Follow Us:
Men and women can respond differently to weight-loss treatments, and this naturally raises an important question: Does Mounjaro work differently for men and women?
Mounjaro contains tirzepatide, a medication that activates both GIP and GLP-1 receptors and can support significant weight reduction when prescribed appropriately. Clinical research has shown meaningful weight loss with tirzepatide in people with overweight or obesity, but the amount of weight lost varies considerably between individuals.
Recent research is also beginning to shed more light on sex-related differences. A 2026 real-world study of more than 1,000 adults treated continuously with tirzepatide for at least 12 months found that women had greater average percentage weight loss than men. However, this does not mean that Mounjaro is ineffective for men or that every woman will lose more weight. Individual factors such as diabetes, dose, starting weight, body composition and treatment adherence also matter.
For people considering Mounjaro injections in Mumbai or other weight loss injections in Mumbai, understanding these differences can help set realistic expectations and encourage a more personalised approach.
The short answer is: the medication can work effectively in both men and women, but the amount and pattern of weight loss may differ.
Clinical trials of tirzepatide have included both men and women, and both groups can achieve substantial reductions in body weight.
However, researchers have increasingly investigated whether sex influences treatment response.
A 2025 systematic review and meta-analysis of GLP-1 receptor agonist studies found that women, on average, experienced somewhat greater weight reduction than men. The analysis included several GLP-1-based medications, so it should not be interpreted as evidence that every person taking tirzepatide will experience the same sex-related difference.
More specifically, a 2026 real-world tirzepatide study found that women achieved an average total body-weight reduction of 15.1% at 15 months compared with 10.7% in men. The researchers also found that higher tirzepatide dosage and absence of type 2 diabetes were independently associated with greater weight loss.
These findings are useful, but averages from a study should never be treated as an individual prediction.
There is no single explanation.
The difference may reflect a combination of biological, metabolic and behavioural factors.
Men and women typically have different proportions and distributions of:
These differences can influence how weight is distributed and how body composition changes during treatment.
Weight loss is not simply about the number displayed on a weighing scale. Changes in fat mass, lean mass and waist circumference can all provide useful information.
Men are more likely to accumulate a greater proportion of fat around the abdomen, while women often have a greater proportion of subcutaneous fat, particularly around the hips and thighs.
These patterns can change with age and hormonal status.
Importantly, this does not mean that one type of fat will always disappear faster. Individual responses vary.
Hormonal status may also influence body composition and appetite regulation.
For women, changes associated with:
can affect body weight and fat distribution.
A 2025 analysis of women participating in the SURMOUNT programme found that tirzepatide was associated with substantial weight and waist-circumference reductions in premenopausal, perimenopausal and postmenopausal groups. This suggests that tirzepatide can be effective across different reproductive stages, although individual responses still vary.
Men should not interpret research showing greater average weight loss in women as a reason to expect poor results.
Men can experience substantial weight reduction with tirzepatide.
In fact, response depends on many variables beyond sex, including:
The 2026 real-world study found that type 2 diabetes status, previous obesity medication use and other medications were associated with treatment response alongside sex.
Therefore, a man's treatment plan should not be based on comparisons with female patients or vice versa.
Yes.
Two people can lose the same percentage of body weight but very different numbers of kilograms.
For example, a 10% reduction in body weight means a larger absolute loss for someone starting at 120 kg than for someone starting at 80 kg.
This is why doctors often consider percentage weight loss, waist circumference and changes in body composition rather than kilograms alone.
Starting BMI and body composition can also influence how a person's results appear over time.
Successful weight management is not just about losing total body weight.
Ideally, treatment should reduce excess fat while helping preserve as much healthy lean tissue as possible.
A body-composition substudy of SURMOUNT-1 found that tirzepatide produced reductions in both fat mass and lean mass, with the majority of weight lost coming from fat mass.
This is important for both men and women.
During weight loss, maintaining muscle can help support:
This is why protein intake and resistance exercise deserve attention during treatment.
Possibly, but it is not possible to prescribe Mounjaro specifically to target abdominal fat.
The body determines where fat is stored and released based on numerous factors.
Tirzepatide can contribute to overall fat loss, which may lead to reductions in waist circumference and abdominal fat. However, it does not selectively burn fat from the stomach, hips, thighs or arms.
For both men and women, waist circumference can be a useful additional measure of progress.
This is particularly relevant because abdominal fat, especially visceral fat, is associated with metabolic health.
Menopause deserves special consideration when discussing weight management in women.
Around menopause, changes in body composition and fat distribution can occur. Many women notice increased abdominal fat, changes in muscle mass and greater difficulty maintaining their previous weight.
This does not mean weight loss becomes impossible.
In the 2025 post hoc analysis of women from the SURMOUNT programme, tirzepatide was associated with significant reductions in body weight and waist circumference across premenopausal, perimenopausal and postmenopausal groups.
However, treatment should still be individualised. Menopause-related symptoms, sleep, physical activity, nutrition and other health conditions may all need consideration.
It can.
People with obesity and type 2 diabetes may respond differently to weight-loss treatment compared with people without diabetes.
This is one reason comparing your results with a friend or an online transformation can be misleading.
In the 2026 real-world study of tirzepatide, the absence of type 2 diabetes was independently associated with greater weight loss.
This does not mean people with diabetes cannot achieve meaningful weight reduction. Rather, it highlights why treatment expectations should be based on individual medical circumstances.
Not everyone is a rapid responder.
Some people lose weight quickly in the early stages, while others experience a more gradual response.
A post hoc analysis of SURMOUNT-1 found that many people categorised as later responders still achieved clinically meaningful weight reduction over a longer treatment period. Among late responders, 90% achieved at least 5% weight reduction by Week 72.
This is an important message for both men and women:
A slow beginning does not automatically mean the treatment will not work.
Your doctor may look at your response over time rather than judging the treatment based on the first few weeks.
Weight loss eventually tends to slow down.
In an analysis of the SURMOUNT-1 and SURMOUNT-4 trials, most participants reached a weight plateau by Week 72. Interestingly, higher doses, younger age and female sex were associated with a longer time to reaching the plateau in that analysis.
A plateau is therefore not necessarily a sign that the medication has failed.
It may simply mean that the body has reached a new equilibrium.
When this happens, doctors can reassess:
There is no universal "male Mounjaro diet" or "female Mounjaro diet."
However, nutritional needs can differ between individuals.
Factors such as body size, muscle mass, activity level, age and health conditions influence dietary requirements.
Regardless of sex, the diet during medical weight loss should generally prioritise:
Protein can help support muscle maintenance and satiety.
Sources may include:
Vegetables, fruits, legumes and whole grains can contribute fibre and micronutrients.
Because appetite may be reduced, choosing foods that provide meaningful nutrition becomes especially important.
Maintaining fluid intake is important, particularly if gastrointestinal symptoms occur.
The exact diet should be adapted to individual needs rather than gender alone.
One misconception is that strength training is mainly important for men.
It is important for everyone.
During weight loss, preserving muscle can support physical function and improve body composition.
For men, resistance training may complement existing muscle mass and help maintain strength as body weight decreases.
For women, strength training can also support muscle preservation, bone health and functional fitness, particularly during midlife and beyond.
A suitable programme may include:
The appropriate intensity depends on your fitness level and medical condition.
No.
Mounjaro contains tirzepatide and is a prescription medication. Whether it is appropriate depends on the individual's medical history, treatment goals, existing conditions and the approved indication applicable to them.
A doctor may review:
Mounjaro also has important contraindications and warnings, so obtaining it without appropriate medical assessment is not advisable.
If you are researching Mounjaro injections in Mumbai, avoid choosing treatment based purely on how quickly another person lost weight.
A responsible medical weight-management programme should consider your individual circumstances.
Your doctor may monitor:
The objective is not simply to achieve the largest possible weight reduction.
It is to achieve meaningful improvement while maintaining adequate nutrition, physical function and long-term health.
Mounjaro is only one medication used in modern medical weight management.
Other treatments may be considered depending on a patient's:
This is why searching for weight loss injections in Mumbai should ideally lead to a medical consultation rather than a decision based solely on online reviews or social media.
The most appropriate treatment is not necessarily the one that produced the biggest result for someone else.
So, does weight loss with Mounjaro differ between men and women? Research suggests that there can be differences in average response, with some recent studies reporting greater percentage weight loss among women. However, sex is only one part of a much larger picture.
Starting weight, body composition, diabetes status, treatment duration, dose, nutrition, activity and individual biology can all influence results. For both men and women, the goal should be meaningful fat loss while supporting muscle, nutrition and overall metabolic health.
If you are considering Mounjaro injections in Mumbai or comparing different weight loss injections in Mumbai, avoid judging your potential results by someone else's experience. Book a consultation with a qualified weight-management doctor to understand whether tirzepatide is appropriate for you and develop a personalised treatment plan based on your health, goals and expected response.
Speak with our medical specialists at MOH Clinics in Mumbai for a personalized evaluation, expert guidance on GLP-1 therapies, customized nutrition planning, and dedicated ongoing care.
Book Consultation